Understanding and Targeting Apoptotic Pathways in Ovarian Cancer

被引：27

作者：

Al-Alem, Linah F. ^{[1
,2
]}

Baker, Andrew T. ^{[1
,2
]}

Pandya, Unnati M. ^{[1
,2
]}

Eisenhauer, Eric L. ^{[1
,2
,3
]}

Rueda, Bo R. ^{[1
,2
,3
]}

机构：

[1] Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Dept Obstet & Gynecol, Boston, MA 02114 USA

[2] Harvard Med Sch, Obstet & Gynecol, Boston, MA 02115 USA

[3] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Gynecol & Oncol Div, Boston, MA 02114 USA

来源：

CANCERS | 2019年 / 11卷 / 11期

关键词：

apoptosis; ovarian cancer; chemoresistance; glycosylation; miRNA; clinical trials; X-LINKED INHIBITOR; CELL-DEATH; CISPLATIN RESISTANCE; DOWN-REGULATION; PROMOTES APOPTOSIS; MUTANT P53; PROTEIN GLYCOSYLATION; MOLECULAR-MECHANISMS; REGULATES APOPTOSIS; GLUCOSE-METABOLISM;

D O I：

10.3390/cancers11111631

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ovarian cancer cells evade the immune system as well as chemotherapeutic and/or biologic treatments through inherent or acquired mechanisms of survival and drug resistance. Depending on the cell type and the stimuli, this threshold can range from external forces such as blunt trauma to programmed processes such as apoptosis, autophagy, or necroptosis. This review focuses on apoptosis, which is one form of programmed cell death. It highlights the multiple signaling pathways that promote or inhibit apoptosis and reviews current clinical therapies that target apoptotic pathways in ovarian cancer.

引用

页数：27

共 172 条

[1] Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells [J].